Major ABO Incompatibility in Non‐Myeloablative Hematopoietic Stem Cell Transplant for Sickle Cell Disease—Not an Insurmountable Obstacle

Documenti analoghi

• Comparing Comorbidity Indices to Predict Survival After Pediatric Hematopoietic Stem Cell Transplantation for Nonmalignant Disease
  di: Roos Lotte Alexandra Bukman, et al.
  Pubblicazione: (2025)
• Increasing Access to Pediatric Allogeneic Hematopoietic Stem Cell Transplantation in South Africa
  di: Candice Laverne Hendricks, et al.
  Pubblicazione: (2026)
• Procedural Sedation outside the Operating Room in Pediatric Hematopoietic Stem Cell Transplant Patients
  di: Heather Xiao, et al.
  Pubblicazione: (2026)
• Response to trametinib Monotherapy Without Hematopoietic Stem Cell Transplant in Juvenile Myelomonocytic Leukemia
  di: Rozalyn Chok, et al.
  Pubblicazione: (2026)
• Analysis of Late Complications Associated With Hematopoietic Stem Cell Transplantation in Patients With Dyskeratosis Congenita
  di: Takashi Koike, et al.
  Pubblicazione: (2025)